Danielle Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danielle Williams has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Angelo M. De Marzo
Departments of Pathology, Urology and Oncology, The John Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland
1 shared publicationJharna R. Das
Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia
1 shared publicationKaren M. Hill
Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia 20059, USA
1 shared publicationLaTonia Taliferro‐Smith
Emory University, Atlanta, Georgia
1 shared publicationMartha Gay
Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia
1 shared publicationSara Kalifa
Department of Pharmacology, Howard University College of Medicine, Washington, District of Columbia
1 shared publication
Latest Publications
- 7 January 2010
- Published by Wiley in The Prostate
- Vol. 70 (7) , 755-764
The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells
BACKGROUND: Class IA PI 3‐kinases produce phosphatidylinositol (3,4,5)‐trisphosphate (PIP3). PIP3 is bound by AKT which facilities its activation by PDK1. Activated AKT promotes cell survival and stimulates cell proliferation. Class IA PI 3‐kinases are heterodimers consisting of a regulatory subunit p85 and a catalytic subunit p110. The p110α isoform has been shown to be mutated in a number of tumor types. A number of recent studies suggest that the p110β isoform may be functionally relevant in prostate cancer. In this study we extend this work to include the examination of the expression and functional properties of p110α and p110β in three different prostate cancer cell lines, DU145, LNCaP, PC3, as well as the non‐tumorigenic but immortalized RWPE1 prostate epithelial cell line.METHODS: Western blot analysis was used to measure protein expression and quantitative real‐time PCR was used to measure mRNA levels. After targeted knockdown using isoform‐specific siRNAs to reduce PI 3‐kinase p110α or p110β isoform expression, we measured downstream signally events such as phosphorylation of AKT, ERK 1/2, PDK, and FOXO, as well as biological consequences such as changes in apoptosis, and alterations in cell cycle progression.RESULTS: In all three prostate cancer cell lines examined, targeted knockdown of p110β, and not p110α, resulted in significantly reduced AKT, PDK, and FOXO phosphorylation. While knockdown of either p110 isoform resulted in an increase in apoptosis and a cell cycle arrest in G1 in the remaining non‐apoptotic cells, these effects were much more pronounced with knockdown of p110β.CONCLUSIONS: Our results support the concept that p110β appears to be the predominant functional class I PI 3‐kinase isoform in prostate cancer cells. Prostate 70: 755–764, 2010.
- 7 January 2010
- Published by Wiley in The Prostate
- Vol. 70 (7) , 755-764
The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells
BACKGROUND: Class IA PI 3‐kinases produce phosphatidylinositol (3,4,5)‐trisphosphate (PIP3). PIP3 is bound by AKT which facilities its activation by PDK1. Activated AKT promotes cell survival and stimulates cell proliferation. Class IA PI 3‐kinases are heterodimers consisting of a regulatory subunit p85 and a catalytic subunit p110. The p110α isoform has been shown to be mutated in a number of tumor types. A number of recent studies suggest that the p110β isoform may be functionally relevant in prostate cancer. In this study we extend this work to include the examination of the expression and functional properties of p110α and p110β in three different prostate cancer cell lines, DU145, LNCaP, PC3, as well as the non‐tumorigenic but immortalized RWPE1 prostate epithelial cell line.METHODS: Western blot analysis was used to measure protein expression and quantitative real‐time PCR was used to measure mRNA levels. After targeted knockdown using isoform‐specific siRNAs to reduce PI 3‐kinase p110α or p110β isoform expression, we measured downstream signally events such as phosphorylation of AKT, ERK 1/2, PDK, and FOXO, as well as biological consequences such as changes in apoptosis, and alterations in cell cycle progression.RESULTS: In all three prostate cancer cell lines examined, targeted knockdown of p110β, and not p110α, resulted in significantly reduced AKT, PDK, and FOXO phosphorylation. While knockdown of either p110 isoform resulted in an increase in apoptosis and a cell cycle arrest in G1 in the remaining non‐apoptotic cells, these effects were much more pronounced with knockdown of p110β.CONCLUSIONS: Our results support the concept that p110β appears to be the predominant functional class I PI 3‐kinase isoform in prostate cancer cells. Prostate 70: 755–764, 2010.